Isofol Medical AB (publ) invites to an audiocast on December 6 at 08.00 a.m. CET
GOTHENBURG, Sweden, December 5, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced on December 3 that the ongoing phase III study AGENT will not reach 300 PFS events with current censoring rules based on FDA decision. Following this announcement, Isofol invites investors, analysts, and media to an audiocast (in English) with a Q&A-session on December 6, at 08:00 a.m. CET.The presentation will be held by Isofol's CEO Ulf Jungnelius and CMO Roger Tell in English and will conclude with a Q&A session. Questions can be asked on the telephone conference or in written form